557 related articles for article (PubMed ID: 19419924)
1. Integrating epidermal growth factor receptor-targeted therapies into platinum-based chemotherapy regimens for newly diagnosed non-small-cell lung cancer.
Pirker R; Minar W; Filipits M
Clin Lung Cancer; 2008; 9 Suppl 3():S109-15. PubMed ID: 19419924
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer.
Ready N
Semin Oncol; 2005 Apr; 32(2 Suppl 3):S35-41. PubMed ID: 16015534
[TBL] [Abstract][Full Text] [Related]
3. Targeted therapy for the treatment of non-small cell lung cancer: focus on inhibition of epidermal growth factor receptor.
Harichand-Herdt S; Ramalingam SS
Semin Thorac Cardiovasc Surg; 2008; 20(3):217-23. PubMed ID: 19038731
[TBL] [Abstract][Full Text] [Related]
4. Extending outcomes: epidermal growth factor receptor-targeted monoclonal antibodies in non-small-cell lung cancer.
Joy AA; Butts CA
Clin Lung Cancer; 2009 Mar; 10 Suppl 1():S24-9. PubMed ID: 19362943
[TBL] [Abstract][Full Text] [Related]
5. Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC).
Metro G; Finocchiaro G; Toschi L; Bartolini S; Magrini E; Cancellieri A; Trisolini R; Castaldini L; Tallini G; Crino L; Cappuzzo F
Rev Recent Clin Trials; 2006 Jan; 1(1):1-13. PubMed ID: 18393776
[TBL] [Abstract][Full Text] [Related]
6. Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.
Murphy M; Stordal B
Drug Resist Updat; 2011 Jun; 14(3):177-90. PubMed ID: 21435938
[TBL] [Abstract][Full Text] [Related]
7. New insights in drug development for the non-small cell lung cancer therapy.
Gridelli C; Rossi A; Maione P; Ferrara C; Del Gaizo F; Guerriero C; Nicolella D; Palazzolo G; Falanga M; Colantuoni G
Front Biosci; 2008 May; 13():5108-19. PubMed ID: 18508573
[TBL] [Abstract][Full Text] [Related]
8. EGFR pathway in advanced non-small cell lung cancer.
Merlo V; Longo M; Novello S; Scagliotti GV
Front Biosci (Schol Ed); 2011 Jan; 3(2):501-17. PubMed ID: 21196393
[TBL] [Abstract][Full Text] [Related]
9. Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.
Vokes EE; Chu E
Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):15-25. PubMed ID: 16736979
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor inhibition in solid tumours.
Ganti AK; Potti A
Expert Opin Biol Ther; 2005 Sep; 5(9):1165-74. PubMed ID: 16120047
[TBL] [Abstract][Full Text] [Related]
11. The role of cetuximab and other epidermal growth factor receptor monoclonal antibodies in the treatment of advanced non-small cell lung cancer.
Rossi A; Bria E; Maione P; Palazzolo G; Falanga M; Gridelli C
Rev Recent Clin Trials; 2008 Sep; 3(3):217-27. PubMed ID: 18782080
[TBL] [Abstract][Full Text] [Related]
12. Cetuximab and other anti-epidermal growth factor receptor monoclonal antibodies in the treatment of non-small cell lung cancer.
Gridelli C; Maione P; Ferrara ML; Rossi A
Oncologist; 2009 Jun; 14(6):601-11. PubMed ID: 19482958
[TBL] [Abstract][Full Text] [Related]
13. Targeted therapies in lung cancer.
Pirker R; Filipits M
Curr Pharm Des; 2009; 15(2):188-206. PubMed ID: 19149612
[TBL] [Abstract][Full Text] [Related]
14. Medical treatment of non-small-cell lung cancer.
Buter J; Giaccone G
Ann Oncol; 2005; 16 Suppl 2():ii229-32. PubMed ID: 15958463
[No Abstract] [Full Text] [Related]
15. Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors.
Blackledge G; Averbuch S
Br J Cancer; 2004 Feb; 90(3):566-72. PubMed ID: 14760365
[TBL] [Abstract][Full Text] [Related]
16. Select clinical trials of erlotinib (OSI-774) in non-small-cell lung cancer with emphasis on phase III outcomes.
Fuster LM; Sandler AB
Clin Lung Cancer; 2004 Dec; 6 Suppl 1():S24-9. PubMed ID: 15638954
[TBL] [Abstract][Full Text] [Related]
17. Targeting epidermal growth factor receptor in lung cancer.
Baselga J; Albanell J
Curr Oncol Rep; 2002 Jul; 4(4):317-24. PubMed ID: 12044241
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor tyrosine kinase inhibitors: application in non-small cell lung cancer.
Thomas M
Cancer Nurs; 2003 Dec; 26(6 Suppl):21S-25S. PubMed ID: 15025409
[TBL] [Abstract][Full Text] [Related]
19. Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study.
Ramalingam S; Forster J; Naret C; Evans T; Sulecki M; Lu H; Teegarden P; Weber MR; Belani CP
J Thorac Oncol; 2008 Mar; 3(3):258-64. PubMed ID: 18317068
[TBL] [Abstract][Full Text] [Related]
20. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
